{
    "2020-06-02": [
        [
            {
                "time": "",
                "orginal_text": "打新直播间 Vol.15 | 医疗届“卖铲”、“挖金”，谁更胜一筹？泰格医药&伟思医疗",
                "features": {
                    "keywords": [
                        "医疗",
                        "泰格医药",
                        "伟思医疗",
                        "卖铲",
                        "挖金"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "高瓴百亿重仓的“卖铲子”行业，干的是医药界富士康的生意？",
                "features": {
                    "keywords": [
                        "高瓴",
                        "医药",
                        "卖铲子",
                        "富士康"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业点评报告：ASCO 2020全球进展解读：免疫疗法依旧亮眼 联合用药大势所趋",
                "features": {
                    "keywords": [
                        "医药生物",
                        "ASCO",
                        "免疫疗法",
                        "联合用药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业投资策略月报：布局高景气度细分领域 聚焦业绩持续增长带来的机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "高景气度",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}